PUBLISHER: DataM Intelligence | PRODUCT CODE: 1247466
PUBLISHER: DataM Intelligence | PRODUCT CODE: 1247466
The global In Situ Hybridization market reached US$ 9700.40 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 15087.46 million by 2030. The market is growing at a CAGR of 11.9% during the forecast period (2023-2030).
In situ hybridization (ISH) uses a labeled complementary DNA, RNA, or modified nucleic acid strand (i.e., probe) to localize a particular DNA or RNA sequence in a portion or section of tissue, or if the tissue is small enough, in the entire tissue (e.g., plant seeds, Drosophila embryos), in cells, and in circulating tumor cells (CTCs). Immunohistochemistry, which often localizes proteins in tissue slices, is different from this.
Smoking and poor eating habits are to responsible for the increase in cancer occurrences. That is a significant growth factor for the ISH market. For instance, the WHO reports that cancer will be the top cause of mortality globally in 2020, accounting for around 10 million deaths, or roughly one in every six. Breast, lung, colon, rectum, and prostate cancers are the most prevalent types of cancer. The use of tobacco, having a high body mass index, drinking alcohol, eating few fruits and vegetables, and not exercising account for about one-third of cancer-related fatalities.
In low- and lower-middle-income nations, cancer-causing infections including the human papillomavirus (HPV) and hepatitis are thought to be the cause of 30% of cancer cases. And as a result, in-situ hybridization demand is increasing during the anticipated period.
The Lack of trained personnel will hamper the market.
To carry out an ISH-based test, one needs to be aware of the molecular specifics of a chromosome or gene. Resistance to the transition from manual to automated procedures is another barrier to the industry's growth. Too many suppliers, making the transfer from manual or antiquated processes to IT-based ones is challenging, if not impossible. Because of this, the broad use of ISH-based diagnosis is limited, particularly in developing countries, by a lack of qualified, educated, and technically adept laboratory personnel.
The global In Situ Hybridization market is segmented based on product, technology, application, end user,and region.
The FISH segment is expected to hold the largest share in the In Situ Hybridization market owing to the increasing number oforthopedic surgeries across the globe. For instance, a chromosome from a person is attached to a glass slide using the Fluorescence In Situ Hybridization (FISH) laboratory procedure, which exposes the chromosome to a probe made of purified DNA that has been fluorescently dyed. It is used to diagnose cancer, chromosomal abnormalities, gene mapping, and genetic illnesses. Growing genetic problems, chronic diseases, and rising demand for effective diagnostic methods are factors in the expansion of the FISH segment. And when more products are released by different market players, the market expands as a result of the rising demand for FISH methods.
For instance, in May 2021, as a part of its newly launched Vizgen release program, Vizgen launched its publicly accessible data collection. The precise location of transcripts from 483 genes can be found in the open-source spatial genomics dataset known as the Vizgen multiplexed error resilient fluorescence in situ hybridization mouse brain receptor map. Therefore, the above-mentioned factors help the FISH segment to dominate the market.
North America'sIn Situ Hybridization market is anticipated to grow in the forecast period owing to increasing product launches by the key players in the region. For instance, because to the region's higher rates of infectious diseases, genetic abnormalities, and cancer, North America is anticipated to hold the majority of the market share for in situ hybridization. The market is also anticipated to increase as a result of increasing research and development efforts, the existence of major industry competitors, and regular product debuts. For instance, estimated numbers of new cancer cases and fatalities in 2022, according of the American Cancer Society (In 2022, there will be an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States.). The 2022 year special section examines the prevalence of cancer risk factors and screening among American Indian and Alaska Native (AIAN) people.
The major global players in the market include Abbott Laboratories, F. Hoffmann-La Roche Ag, Becton, Dickinson And Company, Agilent Technologies, Inc, Thermo Fisher Scientific, Bio-Rad Laboratories, Inc, Bio-Techne Corporation, Creative Bioarray, Biocat Gmbh, Zytovision.
The global In Situ Hybridization market report would provide approximately 61 tables, 58 figures, and 195 Pages.
LIST NOT EXHAUSTIVE